e l f Beauty Inc vs Nuwellis Inc — how do they compare? e l f Beauty Inc trades at $76.34 (market cap $4.37B), while Nuwellis Inc trades at $3.03 (market cap $1.10M). The key difference: e l f Beauty Inc is far larger — about 3972.7× Nuwellis Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| ELF | NUWE | |
|---|---|---|
Market Cap | $4.37B | $1.10M |
Sector | Technology | Technology |
52-Week High | $146.67 | $558.26 |
52-Week Low | $49.57 | $2.80 |
Enterprise Value | $5.00B | -$709.83K |
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $76.11, up 5.34% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins remain thin at 1.61%. Recent analyst coverage is mixed with 46% buy ratings and consensus target of $74.42, slightly below current price. The company demonstrates solid operational cash flow of $133.84M and maintains a healthy balance sheet with $148.69M cash.
Outlook remains positive with continued double-digit sales growth targets, though elevated P/E ratio of 168.68 presents valuation concerns. Key risks include tariff exposure and core brand momentum challenges. Institutional sentiment leans bullish with recent price momentum supported by earnings outperformance and strategic expansion into skincare categories.
Nuwellis (NUWE) trades at $3.22, up 15% in the last 24 hours, following a recent 35:1 reverse stock split executed on June 26, 2026. The medical technology company shows a mixed financial picture with a strong gross margin of 65.47% but significant net losses and negative profitability ratios. Recent news highlights expansion in pediatric care, new patent awards, and a $6 million public offering closed in June 2026 to fund operations. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure.
The outlook remains challenging due to persistent operating losses and negative cash flow, offset by strategic pediatric market expansion and new product innovation. Investment opportunity hinges on the company's ability to translate its high gross margin and recent capital raise into sustainable revenue growth and eventual profitability. Key risks include continued cash burn, execution of commercial strategy, and reliance on financing activities to fund operations.
Trailing returns across standard periods
Latest headlines on both assets
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →